Mesoblast Limited (MEOBF) Receives a Buy from Bell Potter

Business Insider

01-05-2025

Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited (MEOBF – Research Report) today and set a price target of A$3.40.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 4.8% and a 50.60% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mesoblast Limited with a $1.86 average price target.
Based on Mesoblast Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.58 million and a GAAP net loss of $23.97 million. In comparison, last year the company earned a revenue of $1.69 million and had a GAAP net loss of $16.27 million
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MEOBF in relation to earlier this year.